|
Affiliation |
Faculty of Medicine School of Medicine Department of Pathology, Pathophysiology |
|
Title |
Professor |
|
External Link |
|
|
Related SDGs |
|
YAMASHITA Atsushi
|
|
|
Degree 【 display / non-display 】
-
medical doctor ( 2004.3 University of Miyazaki )
-
学士（医学） ( 1997.3 宮崎大学 )
Research Areas 【 display / non-display 】
-
Life Science / Human pathology / PATHOLOGY
Papers 【 display / non-display 】
-
Yamashita A., Oda T., Aman M., Wakasa T., Gi T., Ide R., Todo Y., Tamura N., Sato Y., Itoh H., Asada Y.
BJOG: An International Journal of Obstetrics and Gynaecology 2023
Authorship：Lead author, Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：BJOG: An International Journal of Obstetrics and Gynaecology
Objective: To identify pulmonary/uterine thrombus formation in amniotic fluid embolism (AFE). Design: Retrospective, observational. Setting: Nationwide. Population: Eleven autopsy cases of AFE and control cases. Methods: We assessed pulmonary and uterine thrombus formation and thrombus area in AFE and pulmonary thromboembolism (PTE) as a control. The area of platelet glycoprotein IIb/IIIa, fibrin, neutrophil elastase, citrullinated histone H3 (a neutrophil extracellular trap marker) and mast cell chymase immunopositivity was measured in 90 pulmonary emboli, 15 uterine thrombi and 14 PTE. Main outcome measures: Pathological evidence of thrombus formation and its components in AFE. Results: Amniotic fluid embolism lung showed massive thrombus formation, with or without amniotic emboli in small pulmonary arteries and capillaries. The median pulmonary thrombus size in AFE (median, 0.012 mm2; P < 0.0001) was significantly smaller than that of uterine thrombus in AFE (0.61 mm2) or PTE (29 mm2). The median area of glycoprotein IIb/IIIa immunopositivity in pulmonary thrombi in AFE (39%; P < 0.01) was significantly larger than that of uterine thrombi in AFE (23%) and PTE (15%). The median area of fibrin (0%; P < 0.001) and citrullinated histone H3 (0%; P < 0.01) immunopositivity in pulmonary thrombi in AFE was significantly smaller than in uterine thrombi (fibrin: 26%; citrullinated histone H3: 1.1%) and PTE (fibrin: 42%; citrullinated histone H3: 0.4%). No mast cells were identified in pulmonary thrombi. Conclusions: Amniotic fluid may induce distinct thrombus formation in the uterus and lung. Pulmonary and uterine thrombi formation may contribute to cardiorespiratory collapse and/or consumptive coagulopathy in AFE.
-
Histopathological Features of Cancer-Associated Venous Thromboembolism: Presence of Intrathrombus Cancer Cells and Prothrombotic Factors. Reviewed
Gi T, Kuwahara A, Yamashita A, Matsuda S, Maekawa K, Moriguchi-Goto S, Sato Y, Asada Y
Arteriosclerosis, thrombosis, and vascular biology 2022.11
Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal)
-
Primary Intracranial Ewing Sarcoma Arising from the Cavernous Sinus in an Older Woman with a History of Intensive Breast Cancer Treatment: A Case Report Reviewed
KAWANO Tomoki, MATSUMOTO Fumitaka, YAMASHITA Shinji, OGURI Nobuyuki, AKIZUKI Keiichi, TOMONAGA Takumi, AKIYAMA Yuri, KADOTA Yoshihito, ODA Yoshinao, AZUMA Minako, YAMASHITA Atsushi, OKITA Yoshiko
NMC Case Report Journal 12 ( 0 ) 525 - 530 2025.12
Language：English Publishing type：Research paper (scientific journal) Publisher：一般社団法人 日本脳神経外科学会
A 72-year-old woman with a history of breast cancer presented with left oculomotor nerve palsy. Magnetic resonance imaging revealed a progressive mass lesion in the cavernous sinus. Initially, Tolosa-Hunt syndrome and metastatic brain tumor from breast cancer were suspected; however, radiological differentiation proved challenging. Pathological examination confirmed the diagnosis of primary intracranial Ewing sarcoma. The tumor exhibited progressive growth, and Gamma Knife radiosurgery was performed. After treatment, tumor shrinkage and symptomatic improvement were observed. Ewing sarcoma typically occurs in children and young adults; however, the safety and efficacy of chemotherapy in older populations remain largely unstudied. In this older patient, the rare location of the tumor within the cavernous sinus posed challenges to surgical resection. Chemotherapy was administered at a reduced dose of 50%, with limited side effects. After 7 cycles of chemotherapy, tumor showed further shrinkage, and no recurrence was observed. This case demonstrates that, even in rare tumors with unestablished chemotherapy protocols for older patients, satisfactory outcomes can be achieved with accurate pathological diagnosis and a multidisciplinary treatment approach.
-
Joho T., Zhao S., Nishijima K.I., Ukon N., Shimoyama S., Yamashita A., Washino K., Higashi T., Kobayakawa M., Shiga T., Takahashi K., Ito H.
Annals of Nuclear Medicine 39 ( 9 ) 994 - 1013 2025.9
Language：English Publishing type：Research paper (scientific journal) Publisher：Annals of Nuclear Medicine
Objective: Targeted alpha-particle therapy (TAT) is promising with a greater therapeutic effect than conventional beta radionuclide therapy. To develop human clinical trials of [<sup>211</sup>At]meta-astatobenzylguanidine ([<sup>211</sup>At]MABG), we have conducted an extended single-dose toxicity study of [<sup>211</sup>At]MABG in normal mice in consultation with the Pharmaceuticals and Medical Devices Agency (PMDA). We are currently working for human clinical trials of [<sup>211</sup>At]MABG. After consultation with the Pharmaceuticals and Medical Devices Agency, we conducted a single-dose toxicity study of [<sup>211</sup>At]MABG in normal mice in preparation for a human clinical trial of [<sup>211</sup>At]MABG. Methods: [<sup>211</sup>At]MABG was manufactured at Fukushima Medical University, where doses of 16, 48, and 80 MBq/kg were administered to BALB/cCrSlc mice (90 males and 90 females, 9 weeks old). The mice were observed and weighed every day for 14 days after [<sup>211</sup>At]MABG administration, as well as at any time between 14 and 35 days after [<sup>211</sup>At]MABG administration. At the end of the observation period, necropsy, blood examination, organ weighing, and histopathological examinations were performed. Statistical analyses of body weight, blood test results, and organ weights were performed to compare the data between the control and treatment groups. Results: In the 80-MBq/kg-administered group of females, two mice were emergently euthanized on day 8 because of the deterioration of their general condition. One mouse died spontaneously on day 9. Except for the two emergently euthanized mice and one mouse that died, both males and females showed volume-dependent deterioration in body weight, general condition, necropsy findings, blood test results, organ weights, and histopathological findings, but all except for genital organ weights showed a recovery trend after 35 days. Conclusions: The extended single-dose toxicity study of [<sup>211</sup>At]MABG conducted under the reliability criteria showed the toxicity of [<sup>211</sup>At]MABG to hematopoietic cells, gastrointestinal mucosa, adrenal glands, and genital organs, especially at the dose of 80 MBq/kg. Under the conditions of this study, the approximate lethal dose of [<sup>211</sup>At]MABG exceeds 80 MBq/kg, so the severely toxic dose in 10% of the animals was estimated to be 80 MBq/kg or greater.
-
第5土曜特集 止血･血栓･凝固の最新知見--研究と臨床を繋ぐ 血栓止血関連検査 血栓症の病理診断 Reviewed
魏 峻洸, 山下 篤
医学のあゆみ 294 ( 9 ) 677 - 682 2025.8
Publishing type：Research paper (scientific journal) Publisher：医歯薬出版
Books 【 display / non-display 】
-
モデル動物の作製と利用. 循環器疾患
山下 篤、魏 峻洸、浅田祐士郎（ Role： Joint author , ウサギ反復傷害血栓モデル）
エル・アイ・シー 2021.9
Language：Japanese Book type：Scholarly book
-
モデル動物の作製と利用. 循環器疾患
山下 篤、大栗伸行、浅田祐士郎（ Role： Joint author , 深部静脈血栓モデル）
エル・アイ・シー. 2021.9
Language：Japanese Book type：Scholarly book
-
New Textbook of Clinical Phlebology
（ Role： Contributor）
2019.10
Language：Japanese
-
Thrombosis, atherosclerosis and atherothrombosis: New insights and experimental protocols
Yamashita A, Asada Y（ Role： Joint author）
Intech 2015.12
Language：English Book type：Scholarly book
-
Traditional and novel risk factors in atherothrombosis
Atsushi Yamashita, Yujiro Asada（ Role： Joint author）
Intech 2012.4
Language：English Book type：Scholarly book
MISC 【 display / non-display 】
-
Maekawa K., Nagayasu E., Hata Y., Hanamure F., Maruyama H., Yamashita A.
Pathology International 73 ( 8 ) 373 - 376 2023.8
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Pathology International
DOI： 10.1111/pin.13352
-
冠動脈血栓の病理 Invited
山下 篤、西平賢作、浅田祐士郎
病理と臨床 39 ( 11 ) 1099 - 1105 2021.11
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)
-
ウサギ：ヒトの動脈硬化をウサギで再現 Invited
山下 篤、浅田祐士郎
医学のあゆみ 279 ( 2 ) 169 - 175 2021.10
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)
-
脳梗塞の血管・血栓病理と血栓の形成機序 Invited
山下 篤、浅田祐士郎
Brain and Nerve 73 ( 9 ) 965 - 974 2021.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)
-
アテローム血栓症における血栓形成機序はどこまでわかったのか？ Invited
山下 篤、浅田祐士郎
Heart View 25 ( 1 ) 32 - 38 2021.1
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)
Presentations 【 display / non-display 】
-
血栓症の発症に繋がる血栓の発生および成長機序の解明
山下 篤
第67回日本病理学会秋期特別総会 2021.11.4
Event date： 2021.11.4 - 2021.11.5
Language：Japanese Presentation type：Oral presentation (invited, special)
-
Detection and safety prevention of deep vein thrombosis Invited International conference
Atsushi Yamashita
The 19th International symposium on atherosclerosis 2021.10.26
Event date： 2021.10.24 - 2021.10.27
Language：English Presentation type：Symposium, workshop panel (nominated)
-
破裂性冠動脈プラークの病理とモデル動物のPETイメージング Invited
山下 篤
第53回日本動脈硬化学会総会 2021.10.23
Event date： 2021.10.23 - 2021.10.24
Language：Japanese Presentation type：Symposium, workshop panel (nominated)
-
静脈血栓症の病理 Invited
山下 篤
第43回日本血栓止血学会 2021.5.29
Event date： 2021.5.28 - 2021.5.31
Language：Japanese Presentation type：Symposium, workshop panel (nominated)
-
Histopathological features of cancer-associated venous thromboembolism in human International conference
Gi T, Yamashita A, Matsuda S, Sato Y, Asada Y.
ISTH 2020 Virtual Congress,
Event date： 2020.7.13 - 2020.7.14
Language：English Presentation type：Poster presentation
Awards 【 display / non-display 】
-
日本病理学会学術研究賞
2021.11 日本病理学会 血栓症の発症に繋がる血栓の発生および成長機序の解明
山下 篤
Award type：Award from Japanese society, conference, symposium, etc.
-
第４回ウサギバイオサイエンス研究会優秀発表賞
2016.8 ウサギバイオサイエンス研究会
山下 篤
Award type：Award from Japanese society, conference, symposium, etc. Country：Japan
-
日本血栓止血学会優秀ポスター賞
2010.4 日本血栓止血学会優秀ポスター賞
山下 篤
Award type：Award from Japanese society, conference, symposium, etc. Country：Japan
-
日本病理学会学術奨励賞
2007.3 日本病理学会
山下 篤
Award type：Award from Japanese society, conference, symposium, etc. Country：Japan
-
日本血栓止血学会学術奨励賞
2005.11 日本血栓止血学会
山下 篤
Award type：Award from Japanese society, conference, symposium, etc. Country：Japan
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
薬物送達システムとα線放出核種を組み合わせた革新的な白血病治療法の開発
Grant number：23K27553 2024.04 - 2026.03
独立行政法人日本学術振興会 科学研究費基金 基盤研究(B)
Authorship：Coinvestigator(s)
-
肺血栓塞栓症における非塞栓部肺動脈の変化と静脈血栓由来因子の解明
Grant number：23K06467 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費基金 基盤研究(C)
Authorship：Principal investigator
-
薬物送達システムとα線放出核種を組み合わせた革新的な白血病治療法の開発
Grant number：23H02862 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(B)
Authorship：Coinvestigator(s)
-
妊産婦死亡の主因である羊水塞栓症における血栓性病態の解明
Grant number：22K06961 2022.04 - 2025.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
阿萬 紫、
Authorship：Coinvestigator(s)
-
静脈血栓塞栓の質的診断に繋がるDual-energyCTによる血栓の成分解析
Grant number：21K07706 2021.04 - 2025.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
古小路 英二、
Authorship：Coinvestigator(s)
Other research activities 【 display / non-display 】
-
血栓止血用語集
2012.04 - 2015.12
血栓止血用語集の編集委員